Outset Medical, Inc. (NASDAQ:OM) General Counsel John L. Brottem Sells 20,492 Shares

Outset Medical, Inc. (NASDAQ:OM) General Counsel John L. Brottem sold 20,492 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $0.81, for a total value of $16,598.52. Following the completion of the sale, the general counsel now owns 205,028 shares in the company, valued at approximately $166,072.68. This represents a 9.09 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Outset Medical Trading Down 12.2 %

Shares of OM opened at $0.81 on Tuesday. The company has a debt-to-equity ratio of 4.12, a current ratio of 6.49 and a quick ratio of 5.04. Outset Medical, Inc. has a 1-year low of $0.44 and a 1-year high of $5.22. The stock has a market cap of $42.44 million, a price-to-earnings ratio of -0.29 and a beta of 2.05. The firm has a 50 day simple moving average of $1.01 and a 200-day simple moving average of $1.41.

Hedge Funds Weigh In On Outset Medical

Several hedge funds have recently bought and sold shares of OM. Vanguard Personalized Indexing Management LLC acquired a new stake in Outset Medical during the second quarter worth approximately $49,000. National Bank of Canada FI lifted its stake in shares of Outset Medical by 79.2% during the 3rd quarter. National Bank of Canada FI now owns 52,407 shares of the company’s stock worth $35,000 after purchasing an additional 23,164 shares during the period. Huntington National Bank boosted its holdings in shares of Outset Medical by 46.2% during the third quarter. Huntington National Bank now owns 63,306 shares of the company’s stock worth $43,000 after purchasing an additional 20,000 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Outset Medical in the second quarter valued at $259,000. Finally, Squarepoint Ops LLC increased its stake in Outset Medical by 74.1% in the second quarter. Squarepoint Ops LLC now owns 80,300 shares of the company’s stock valued at $309,000 after purchasing an additional 34,187 shares during the last quarter.

Wall Street Analysts Forecast Growth

Separately, Royal Bank of Canada reissued a “sector perform” rating and issued a $3.00 target price on shares of Outset Medical in a report on Tuesday, January 7th.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.